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Mouse mon~lonal antibodies were prepared against ~-galactosidase (EC 3.2.1.23) of Escherichia colt. The binding sites of these monocional anti- 
bodies within the ~-gala~tosida~ molecule were estimated by i~~oblot analyses to various defined peptide regions of ~-galactosida~, encoded 
by expression plasmids. Mon~lonal antibodies‘were characterised, which either bind to the amino-te~inal or to the carboxy-te~inal region or 
to an internal section of p-galactosidase. These defined monoclonal antibodies were shown to be a useful tool for characterisation of j%galactosidase 
fusion proteins expressed in Escherichia coli. 
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1. INTRODUCTION 
Eukaryotic proteins synthesized in E. cofi were often 
found to be rapidIy degraded in the microbial host 
unless these proteins were fused to an E. co& protein. 
One of the most common techniques for making fusion 
proteins is the E. coli 1acZ system coding for fl- 
galactosidase. Efficient vectors have been constructed 
to facilitate the expression of bi- or tripartite p- 
galactosidase hybrid proteins [1,2]. When the fusion 
protein is used to elicit antibodies against he cloned an- 
tigen, it is desirable to reduce the /3-galactosidase por- 
tion of about 116 kDa of the hybrid protein. This is 
especially the case, when the cloned peptide is small and 
the ratio to @-galactosidase therefore is unfavourable. 
For this purpose, expression plasmids have been con- 
structed that direct the regulated high synthesis of pro- 
teins or protein fragments fused to truncated forms of 
P-galactosidase (@gab) [3,4]. These vectors facilitate the 
production of heterologous polypeptides fused to fl- 
galactosidase fragments of only some hundred amino 
acids instead of more than thousands as encoded by the 
entire @-galactosidase [S]. The.fusion proteins can im- 
munologically be identified by serum, which is specific 
for the polypeptides fused to the @gal sequences. 
Whenever such a serum is not available, or when the 
serum is not reactive with the recombinant counterpart, 
such a hybrid protein can be detected by serum directed 
against ,&galactosidase. However, polyclonal anti-@- 
galactosidase sera often react UnspecificaIly, because 
the material used for immunisation is not totally free of 
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E. coli contaminants or the animals have been i  con- 
tact with E. coli and have produced antibodies directed 
to the bacteria. Therefore, we have prepared 
monoclonal antibodies (mabs) to @-galactosidase, 
which are highly specific and sensitive and which show 
no cross-reactivity with other E. cofi proteins. The 
usefulness of these mabs, of which the binding site to 
P-galactosidase could be identified, is shown in some 
examples and further applications are discussed. 
2. MATERIALS AND METHODS 
2.1. DNA methods 
DNA manipulations were done according to [6]. DNA fragments 
were isolated from low melting agarose according to Wieslander [7] 
and mini prep analyses were carried out as described by Holmes and 
Quigley [8]. Expression of IacZ and 1acZ coding DNA fragments were 
carried out in E. coti BMH 71-18 (lac pro)A thi .~pEfl’ 
lacPZ_AMlS pro+) 191. 
2.2. Ptasmids 
The following vectors, coding for IacZ and truncated lacZ 
sequences, were used in this study: pUR278 [l], pWR590 131, pBD1, 
pBD2 and pBD5 [4]. Plasmid pBD2-IC20H is a derivative of pBD2 
with a polylinker downstream of the DNA coding for @gal, [lo]. The 
expression of 1ucZ is under the control of the lac promoter and was 
induced by addition of IPTG to the bacterial cultures. 
The plasmid pMB253 codes for a fusion protein consisting of /3galt 
and the C domain of the human antihaemophilic factor VIII. The 
plasmid was made by cloning the 2450 bp CtaI-XhoI DNA fragment 
coding for factor VIII [I l] into pBD2-IC20H [lo] cut with SmaI and 
Xhol such that the factor VIII antigen is in frame to the @- 
galactosidase portion. 
The vector pB03 codes for the synthesis the herpes simplex virus 
type 1 envelope glycoprotein gC. The gC antigen is made as a tripar- 
tite fusion protein and is sandwiched between the amino-terminus of 
c1 repressor protein and the entire @-galactosidase (cI::gC:$gaI). The 
expression of the pB03 encoded hybrid protein is controlled by the 
tat promoter [2]. 
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2.3. Imuunological procedures 
Extracts of E. co/i cells expressing /3-galactosidase or fl-galac- 
tosidase fusion proteins were separated in 8-12’70 SDS-PAGE and 
were transferred to nitrocellulose sheets (Schleicher and Schuell). 
Western blot analyses were done according to Burnette [12]. The con- 
centration of the individual mabs was 10 wgg/ml in the buffer solu- 
tion. Alkaline phosphatase coupled anti-mouse antibodies were used 
as conjugate with Fast blue B salt (Serva) and naphthol AS-MX 
Phosphate (Sigma) as substrates. Extracts of the fl-galactosidase defi- 
cient E. coli strain MC4100 (araDl39, A(argF-lac) U169, rpsL150, 
relA1, flb5301, deoC1, ptsF25rbsR) [13] served as negative control 
antigen. 
2.4. Preparation of monoclonal anti-enqwne antibodies 
4-6-week-old Balb/c mice were immunized subcutaneously and/or 
intraperitoneally with 20 fig of &galactosidase in Freund’s complete 
adjuvant. Four weeks later, mice were boostered with 10 gg of fl- 
galactosidase in incomplete Freund’s adjuvant. Prior to fusion, mice 
were boostered intraveneously 4 times at daily intervals. Spleen cells 
were isolated aseptically and were fused with the myeloma cell line SP 
2/o using polyethylene glycol (PEG) according to standard methods. 
The final cell pellet was resuspended in DMEM containing 20% calf 
serum and HAT (0.1 mM hypoxanthin, 0.004 mM aminopterin, 
0.016 mM thymidine) and added to 24-well culture plates (Nunc). 
About 14 days later, individual cell clones were picked out and were 
transferred to a new well. Three days later, supernatants were tested 
for antibody content as well as for the presence of fl-galactosidase- 
specific antibodies. Positive cell cultures were grown up and were 
frozen in liquid nitrogen. In parallel, positive cell lines were cloned 
using a single cell manipulator. 
2.5. Screening of monoclonal antibodies 
Supernatants were screened using @galactosidase-coated microti- 
tration plates. Mabs bound to the solid phase were demonstrated by 
a second incubation with horseradish peroxidase (HRP) labelled rab- 
bit anti-mouse antibodies. Relative affinity of anti-/3-galactosidase 
mabs was determined by incubating defined concentrations of dif- 
ferent antibody containing supernatants on fl-galactosidase-coated 
microtitration plates. 
2.6. Production and purification of mabs 
Cell lines producing anti &galactosidase mabs were propagated as 
ascites fluids using IFA-primed Balb/c mice. Immunoglobulins were 
purified by affinity chromatography using Protein A-Sepharose 
(Pharmacia/LKB) according to the manufacturer. Purity was 
monitored by HPLC and SDS-PAGE (Phast System, Phar- 
macia/LKB). Protein concentration was determined by optical densi- 
ty measurement at 280 nm. Class and subclass isotypes were 
determined by double diffusion techniques (Miles). 
3. RESULTS 
3.1. Identification of anti-fl-galactosidase mabs 
Fifteen anti-&galactosidase mabs were isolated, 
which recognized @-galactosidase bound in microtiter 
plates and which also reacted with P-galactosidase in 
Western blots. Seven mabs were further analyzed with 
respect to the binding site within the P-galactosidase 
molecule. The mabs 87-55/60,87-134/202,87-1341238, 
87-179103, 87-179/20 and KG12 belong to the subclass 
IgGr, while 87-1761103 was of IgGza subtype. 
3.2. Localization of the antigenic determinants 
recognized by the mabs 
To localize the binding site of the mabs within the fl- 
galactosidase molecule, we made use of expression vec- 
tors, which code for the entire &galactosidase or for 
defined fl-galr fragments of different length (fig.1). 
Cells carrying the plasmid pUR278 synthesize the total 
/3-galactosidase protein, while the vectors pBD1, 
pWR590 and pBD2 code for truncated forms beginning 
from the amino-terminus until amino acid Leu6’l, 
Asn583 or ASHES’, respectively. The vector pBD5 codes 
for a fusion protein in which the carboxy-terminal por- 
tion of fi-galactosidase from GIu~~’ to Phe”” is fused 
to a short P-galactosidase leader [4]. These two @- 
galactosidase segments are separated by a stretch of the 
herpes simplex virus glycoprotein D antigen (indicated 
by a line in fig.1). These 5 polypeptides, carrying dif- 
ferent but in part overlapping P-galactosidase antigenic 
regions, were expressed in E. coli. Total cell extracts 
from these transformants and extracts from the 
plasmid-free and /3-galactosidase-deficient E. coli strain 
MC4100 and a protein molecular weight mixture in- 
cluding P-galactosidase as antigen were separated by 
@JR278 
pBO1 
pWR590 
pBO2 
pBO5 
1 
G’%eo Pha1007 
Fig.1. Scheme of the fl-galactosidase polypeptide portions which are encoded by the various expression plasmids. The thin line in the 
pBD5-encoded protein represents a polypeptide stretch of the herpes simplex virus glycoprotein gD which is in frame with the amino-terminal 
and the carboxy-terminal portion of @-galactosidase [4]. 
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Fig.2. Reaction pattern of mab 87-S/60 in Western blots with defin- 
ed fl-galactosidase portions. Cell extracts from E. coli BMH-71-18, 
expressing different fi-galactosidase segments, extracts from E. coli 
MC4108 and molecular weight marker proteins (Sigma) were blotted 
and incubated with mab 87-55160. The lane with the marker proteins 
contains myosin, ~-galactosidase, phosphorylase, bovine albumin, 
egg albumin and carboanhydrase. The @-gaIactosidase polypeptides, 
which were recognized by the mab, are indicated by an arrow. 
SDS-PAGE and were blotted onto nitrocellulose mem- 
branes . 
Fig.2 documents the reactivity of mab 87-55/60 to 
the various P-galactosidase polypeptides encoded by 
the expression vectors. Mab 87-55’60 recognized /3- 
galactosidase antigens specified by the plasmids 
pUR278, pBD1, pWR590 and pBD2, but did not react 
with the &galactosidase segment encoded by pBD5 
neither did it bind to proteins from the ~-galactosidase- 
deficient E. cob strain MC4100. From this reaction pat- 
tern it can be concluded, that mab 87-55/60 binds to an 
epitope within the amino-terminal region from Thr’ to 
Asp375 of the fl-galactosidase molecule (table 1). The 
binding sites of the other 6 mabs were determined in the 
same way and the results are overviewed in table 1. 
Three binding classes of @-galactosidase-specific mabs 
were defined by this procedure: class 1 mabs bind to the 
@-galactosidase amino-terminus from Thr’ to Asp375, 
class 2 mabs recognize epitopes within the central part 
of @galactosidase from IIe376 to Leu651 and class 3 
mabs react with the carboxy-terminal portion specified 
by the amino acid sequence from Gl@’ to Phe’007. 
3.3. Characterization of the tripartite cI::gC:: figal fu- 
sion protein 
We have previously made use of the expression vec- 
tor pMF2 [2f to synthesize tripa~ite fusion proteins of 
the order cI::gene X:$gal in E. coli. When gene X 
within these hybrid proteins was represented by a long 
stretch of the herpes simplex virus type 1 (HSV-1) 
glycoprotein C (gC), the expression products encoded 
by the vector pB03 (see section 2) were rapidly degrad- 
ed. This cI::gC:$gal fusion protein could not be iden- 
tified in E. cob extracts by SDS-PAGE separation and 
staining with Coomassie brilliant blue. The entire fu- 
sion protein could not be detected in Western blots but 
only by radio-immunoprecipitation, when a polyclonal 
serum directed to HSV-1 was used. The high sensitivity 
of 3 mabs, representing either class 1, class 2 or class 
3 (table 1) is documented in fig.3. The mab 87-55’60, 
mab 87-179/03 and mab 87-176/103 reacted with the 
pUR278 encoded &galactosidase (lane 1) and with the 
small amount of the entire cI::gC::pgal fusion protein 
of molecular mass 182 kDa encoded by ~I303 (lane 2). 
In addition, a few degradation products can be 
recognized by mab 87-55160 (fig.3A/2), some more can 
be seen by mab 87-179/03 (fig.3B/2) and the bulk is 
visualized by mab 87-1761103 (fig.3C/2). We assume 
that P-galactosidase sequences in the neighbourhood of 
the gC antigen are preferentially degraded by proteases 
and therefore epitopes in the amino-terminal region of 
@-galactosidase are lost faster than those located in the 
middle or carboxy-terminal region. This would explain 
the increasing number of bands which appear in the 
blots by using the mabs in the order: mab 87-55/60, 
mab 87-179/03 and mab 87-1761103 (fig.3A,B,C, lanes 
2). 
The mabs recognized not only fl-galactosidase, ,&galt 
or fusion proteins of type gene X:$-galactosidase, but 
also E. coli expression products of type /3gal::gene X
and @gaI,::gene X. All fusions tested so far were iden- 
tified in Western blots with a variety of viral or human 
polypeptide stretches represented by gene X (un- 
published results). 
Table 1 
Reaction pattern of the’defined @galactosidase segments with 7 individual mabs and the deduced binding sites of 
the mabs 
mab Immunoreaction binding site class 
87-55/60 
87-134/202 
87-134/238 
pUR278 pBD1 pWR590 pBD5 pBD2 
+ f + - + Thr’-Asp’75 1 
+ + + + Thr’-Asp375 
+ + + - + Thrr-Asp”’ 
87-179103 + + + 
87-179/20 + + + 
_ Ile3’6-Leu65’ 2 
- - Ile375-Leu65’ 
87-176/103 + 
KG12 + 
+ - Glu650-Phe’w7 3 
_ - f Glu650-Phe’~7 
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cloned the cDNA coding for factor VIII from GIu’~’ 
to Tyrz3” in frame to the figah encoded by 
pBD2-IC20H Ill] to yield the vector pMB253 (for 
detailed cloning procedure see section 2). The 
~gal~::factor VIII fusion protein (== 117 kDa) is 
relatively unstable in E. co& and degradation products 
of the fusion protein can be detected when total cell ex- 
tracts of E. coli IpMB2531 are separated by SDS-PAGE 
and are stained with Coomassie brilliant biue (data not 
shown). Western blot analyses with polyclonal anti fac- 
tor VIII serum and anti @-galactosidase mab 87-5960 
were helpful to analyze the expression of recombinant 
factor VIII antigens in I?. coli (fig.4). Without induc- 
tion of the lac promoter, no pMB253-encoded fusion 
protein could be detected neither in Coomassie brilliant 
blue-stoned gels (data not shown) nor in Western blots 
by using the polyclonal anti-factor VIII rabbit serum. 
Nevertheless, the mab 87-55160 detected the fusion 
Fig.3. Sensitivity of three individual mabs. Western blot analyses 
with extracts from E. coli [p~~Z78], expressing entire @- 
galactosidase (iane 1) and E. coli [pBO3], expressing the hybrid pro- 
tein cI::gC:$gaI (lane 2) with mab 87-45160 (A), mab 87”179/03 (B) 
and mab 87-176/103 (C). The reaction with the entire fusion protein 
is indicated by an arrow. 
protein (fig.4, filled circle) and the figa& (fig.4, filled 
square) encoded by pBD2 in such cell extracts, in- 
dicating a basai expression, because the lac promoter 
was not totally repressed in this system, although the 
expression host E. coli strain BMH 71-18 is an over- 
producer of the lac repressor protein. 
3.4. ~~fere~t~atiu~ of proteo~tica~~~ ~e~ra~e~ p- 
ga~actosidase and factor VIH specific antigenie 
deter~i~u~ts derived from a @ga&::fuctor WI1 
fusion protege 
In order to rise polyclona1 antisera to the C domain 
of the human blood coagulation protein factor VIII, we 
However, the mab 87-55/60 did apparentIy not re- 
spond in proportion to the induced level of the fusion 
protein (fig,LtB, lane 3 versus lanes 43). The reason for 
this failure is not known yet. 
In any case, degradation products predominantIy 
carrying epitopes specific for P-galactosidase (fig.4, 
open star) or factor VIII (fig.4, triangle) could be 
Fig.4. Differentiation between @gaIactosidase-specific and factor VIII-specific polypeptide stretches. Western blot analyses with polycional anti- 
factor VIII serum (A) and mab 87-55/60 (B). Molecular weight marker proteins (lane 1); E. co& IpBDZ]-induced culture expressing alr (lane 2); 
E. coil [pMB253], uninduced culture (lane 3); E. co& ipMB2531, induced culture, expressing the ~gal~::factorVIII fusion protein, harvested 1 h 
after induction (lane 4), or after 4 h (lane 5). The filled square indicates the position of the pgak encoded by pBD2, the filled star the entire @- 
galactosidase, the filled circle marks the position of the entire @gak::factor VIII fusion protein and a partial degradation product of about 116 
kDa, the open star indicates the ~-g~a~tosidas~s~ific degradation products, and the fihed triangle factor VIII-specific degradation products. 
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distinguished by using the different antibodies. This 
specific analysis enabled us to unequivocally identify 
factor VIII-specific degradation products and to isolate 
such immunostained bands from the nitrocellulose 
sheet in order to raise polyclonal monospecific anti- 
factor VIII antibodies by the procedure described by 
Sandkamp et al. [14]. 
4. DISCUSSION 
In this paper, we present mabs which have been rais- 
ed against the E. coli @galactosidase. By use of 
Western blot analyses with distinct recombinant /3- 
galactosidase polypeptide fragments, we could identify 
the binding regions within the fi-galactosidase 
molecule. Due to the cloned fl-galactosidase segments, 
3 classes of binding regions were determined: the 
amino-terminal region, the central part and the 
carboxy-terminal region. Construction of further 
plasmids, that direct the synthesis of even smaller trun- 
cated /3-galactosidase s gments and synthetic peptides 
could allow a still more precise epitope mapping. 
The mabs were shown to be highly sensitive and 
specific and can improve the identification of recombi- 
nant expression products by Western blot analyses. 
Furthermore, the mabs can be used for im- 
munoprecipitation studies, in immunofluorescence 
techniques (unpublished observations) and possibly for 
purification of /3-galactosidase fusion proteins by im- 
munoaffinity chromatography. Whenever the synthesis 
of the E. coli lacZ gene in bacteria, yeast, plant or 
animal tissue culture cells has to be monitored as a 
means of marker for transcriptional/translational con- 
trol, the immunological detection of /3-galactosidase 
with the aid of these mabs may be an alternative for the 
measurement of enzymatic activity of /3-galactosidase. 
In addition, monoclonal antibodies recognizing in- 
tact P-galactosidase without affecting enzymatic activi- 
ty can be used to develop highly sensitive detection 
systems based on fi-galactosidase/anti-/3-galactosidase 
complexes bridged with an unlabelled anti-mouse an- 
tibody. 
These complexes could be an alternative for the 
preparation of covalent antibody/enzyme conjugates 
or can be used very effectively in combination with 
bispecific monoclonal antibodies having one binding 
site for the analyte and the other one for /3- 
galactosidase. In addition, the sensitivity of enzyme im- 
munoassays can be increased by amopification steps us- 
ing repeated incubations of enzyme/anti-enzyme 
complexes. 
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